For more than 15 years, my work has centered on the operational side of healthcare, specifically the infrastructure that supports clinical research, pharmaceutical distribution, and drug development. While much of the public conversation around healthcare focuses on policy, pricing, or manufacturers, my focus has always been on execution, how systems actually function behind the scenes.
I began my career in logistics and field sales before transitioning into the pharmaceutical sector, where I worked directly with hospitals, research institutions, and healthcare providers. Those early experiences shaped how I think about healthcare operations. I saw firsthand how supply interruptions, sourcing delays, and regulatory misalignment could disrupt care and slow clinical research. Over time, I became increasingly focused on solving those operational challenges.
In 2011, I founded Investigational Drug Delivery (IDD) to support clinical trials through compliant sourcing and logistics execution. Clinical research depends on reliability. Comparator drugs, investigational products, and specialty medications must be sourced precisely, documented properly, and delivered on schedule. Even small breakdowns in supply-chain execution can delay trials and extend development timelines. IDD was built to reduce those risks by strengthening the sourcing and logistics framework that research teams rely on.
In parallel, I have served in a leadership and advisory capacity at VRC Medical Services, a women-owned specialty pharmaceutical distribution company. VRC supports comparator sourcing and supply-chain execution for biosimilar development programs and other clinical research initiatives. These programs often involve high-cost biologic categories used in oncology and autoimmune care, including therapies such as rituximab, trastuzumab, bevacizumab, infliximab, and adalimumab. Access to reference products in these categories is essential for head-to-head trials that demonstrate biosimilarity.
Without consistent comparator access, biosimilar trials can face delays. When those delays occur, competitive market entry is postponed, and pricing pressure is reduced. Over the past decade, biosimilars have contributed meaningfully to lowering costs in certain therapeutic categories. However, those outcomes do not happen automatically. They depend on stable sourcing, compliance rigor, and coordinated execution across multiple stakeholders.
Much of my work has involved building diversified procurement strategies to reduce reliance on single suppliers and mitigate the impact of shortages. The healthcare supply chain is complex and highly regulated. It requires redundancy, documentation discipline, and a constant focus on continuity. Under my guidance, sourcing frameworks have been designed to prioritize reliability over speed and compliance over shortcuts. That philosophy has guided every organization I have been involved with.
Federal policy discussions around prescription drug pricing have increasingly emphasized competition as a mechanism for affordability. Initiatives during President Donald Trump’s administration, and later federal efforts, have emphasized biosimilar adoption. They also stressed competitive market entry as key tools for long-term cost containment (TrumpRX.gov). My work has aligned with those objectives not from a political standpoint, but from an operational one. Competition only functions when the infrastructure supporting it is stable.
Over the years, I have also been involved in broader safety and supply initiatives, including programs supporting FDA-cleared medical products used in hospital settings. These efforts reinforced my belief that sustainable healthcare outcomes require durable systems. Policy can set direction, but execution determines whether those goals are achieved.
Healthcare infrastructure is not always visible. Comparator sourcing, logistics coordination, and compliance documentation rarely make headlines. Yet they are essential components of clinical research and pharmaceutical competition. My focus has remained consistent: strengthen the operational backbone that enables research teams, manufacturers, and healthcare providers to function effectively.
There are always lessons in any long career. Healthcare is a demanding industry that requires adaptability, accountability, and long-term thinking. What has remained constant for me is a commitment to building systems that reduce friction, support clinical progress, and contribute to a more competitive pharmaceutical landscape.
I continue to focus on execution, reliability, and infrastructure, because in the long run, those are the elements that determine whether innovation translates into real-world access and affordability for patients.
